Loading
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Latest quote
$14.58
+$0.36 · +2.53%
After-hours
$14.58
$0.00 · 0.00%
Oct 9, 4:01 PM ET
Regular session · ET · Market data may be delayed.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Day range
Current $14.58
52-week range
Current $14.58
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
76
Undervalued
Sentiment
65
Bullish
Risk
47
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Day range
Current $14.58
52-week range
Current $14.58
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 655.35M USD | 605.22M USD | 509.34M USD | 537.84M USD | 535.03M USD |
| Cost of goods sold | 166.88M USD | 137.18M USD | 128.28M USD | 114.87M USD | 114.88M USD |
| Gross profit | 488.47M USD | 468.04M USD | 381.06M USD | 422.97M USD | 420.15M USD |
| Research and development | 224.54M USD | 209.65M USD | 223.06M USD | 206.09M USD | 201.3M USD |
| Selling, general, and administrative | 417.73M USD | 428.89M USD | 390.87M USD | 306.41M USD | 263.18M USD |
| Operating expenses | 642.27M USD | 638.54M USD | 614.67M USD | 512.5M USD | 464.49M USD |
| Interest income | 18.11M USD | 51M USD | 46.04M USD | 15.79M USD | 1.1M USD |
| Interest expense | — | 11.66M USD | 4.91M USD | 8.11M USD | 8.84M USD |
| Depreciation and amortization | 14.65M USD | 11.24M USD | 10.97M USD | 10.62M USD | 10.25M USD |
| Operating income | −153.8M USD | −170.5M USD | −232.87M USD | −89.52M USD | −44.33M USD |
| Net income | −136.23M USD | −168.63M USD | −207.04M USD | −92.53M USD | −58.35M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$26.00
78.33% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI61.74M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB44.65M0.02%185.3B USD0.03%$289.48+0.64%
iShares Russell 2000 ETFIWM39.94M0.05%77.7B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK25.58M0.06%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF21.59M0.02%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO13.06M0.09%14.04B USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB11.54M0.11%10.41B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO10.85M0.06%18B USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
